Andree Blaukat
5PUBLICATIONS
45CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Feb 28, 2025
M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer.Christina Esdar, Nina Linde, Andreas Blum
|Nov 08, 2023
Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models.Manja Friese-Hamim, Maria J Ortiz Ruiz, Olga Bogatyrova
|Apr 20, 2023
Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.Audrey Turchick, Astrid Zimmermann, Li-Ya Chiu
|Mar 31, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.Joachim Albers, Manja Friese-Hamim, Anderson Clark
|Apr 11, 2022
A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.Astrid Zimmermann, Frank T Zenke, Li-Ya Chiu
Pageof 1
Frequent Collaborators
3 joint publications
Frank T Zenke
2 joint publications
Astrid Zimmermann
2 joint publications
Li-Ya Chiu
2 joint publications
Heike Dahmen
2 joint publications
Beatrix Blume
2 joint publications
Birgitta Leuthner
2 joint publications
Manja Friese-Hamim
1 joint publications
Ulrich Pehl
1 joint publications
Thomas Fuchss
1 joint publications
Thomas Grombacher
